Reduction in systemic glucocorticoid utilization among COPD patients with type 2 inflammation treated with biologics

Abstract Background Systemic glucocorticoids are associated with significant side effects, however, are essential in the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD). Biologic therapies in COPD with type 2 (T2) inflammation have shown benefit in reducing exacerbat...

Full description

Saved in:
Bibliographic Details
Main Authors: Truong-An A. Ho, Stephen Dachert, Anugya Mittal, Gerard J. Criner
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Pulmonary Medicine
Subjects:
Online Access:https://doi.org/10.1186/s12890-025-03809-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items